A Phase 2 interventional study of TAK-954 and Placebo in Diabetic Gastroparesis and Idiopathic Gastroparesis, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-07.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 67th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 38 in phase 2, and was the 84th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 3 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
The drug being tested in this study is called TAK-954. TAK-954 is a serotonin (5 HT4) receptor agonist and is being tested to treat people who have diabetic or idiopathic gastroparesis and who previously reported delay in stomach emptying. This study will look at the gastric emptying time of solids in people who take TAK-954 or placebo.
The study will enroll approximately 41 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
This single center trial will be conducted in the United States. The duration of treatment is 3 days and the overall period of evaluation is up to 28 days. The participants will be contacted by telephone (Days 10 to 14) for follow-up assessment. There will be another follow-up phone call for women of childbearing potential (Days 38 to 43).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Are without known preexisting hepatic disease who have 1 or more of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
Drug: Placebo
TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
Drug: TAK-954
TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
Drug: TAK-954
TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
Drug: TAK-954
TAK-954 IV infusion.
TAK-954 placebo-matching IV infusion.
Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids
Half-emptying time (t1/2) of gastric solids is the time for half of the ingested solids or liquids to leave the stomach. Scintigraphy assessments were used to evaluate the gastric emptying of solids following a radio-labelled meal. A negative percent change from baseline indicated improvement.
Time frame: Predose and at multiple time-points post-dose (up to 9 hours) on Day 2
Colonic Geometric Center
The scintigraphic method was used to measure colonic geometric center following a radio-labelled meal. The geometric center (GC) was the weighted average of counts in the different colonic regions, where 0= no radioactivity in the colon and if radioactivity was detected in the colon, 1=all isotope was in the ascending colon and 5=all isotope was in the stool; a high GC indicated faster colonic transit.
Time frame: 4, 24, and 48 hours post-radiolabeled meal on Day 2
Colonic Filling at Hour 6
Colonic filling was estimated as percentage of the radio-labelled meal that reached the colon at Hour 6.
Time frame: 6 hours post-radiolabel meal on Day 2
Half-emptying Time (T1/2) of Ascending Colon
T1/2 of ascending colon emptying was estimated by analysis of proportionate emptying over time of counts from the colon. Scintigraphy assessments were used to evaluate the emptying of solids or liquids from ascending colon following a radio-labelled meal.
Time frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3
AUCtau: Area Under the Plasma Concentration-Time Curve From Time 0 to t for TAK-954
Time frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3
Cmax: Maximum Observed Plasma Concentration for TAK-954
Time frame: Predose and at multiple time-points post-dose (up to 25 hours) on Days 1, 2 and 3
Ctrough: Observed Plasma Concentration at the End of a Dosing Interval
Time frame: At multiple time-points post-dose, up to 9 hours on Day 2 and up to 25 hours on Day 3
Participants took part in the study at 1 investigative site in the United States from 02 January 2018 to 12 July 2019.
| Milestone | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Started | 10 | 10 | 9 | 7 |
| Completed | 9 | 10 | 9 | 6 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Half-emptying time (t1/2) of gastric solids is the time for half of the ingested solids or liquids to leave the stomach. Scintigraphy assessments were used to evaluate the gastric emptying of solids following a radio-labelled meal. A negative percent change from baseline indicated improvement.
| percent change | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids | 3.5 ± 23.71 | -19.8 ± 14.43 | -25.4 ± 20.90 | -25.7 ± 23.56 |
The scintigraphic method was used to measure colonic geometric center following a radio-labelled meal. The geometric center (GC) was the weighted average of counts in the different colonic regions, where 0= no radioactivity in the colon and if radioactivity was detected in the colon, 1=all isotope was in the ascending colon and 5=all isotope was in the stool; a high GC indicated faster colonic transit.
| score on a scale | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Colonic Transit at 4 Hours, Day 2 | 0.539 ± 0.6809 | 1.190 ± 0.9083 | 1.737 ± 1.0302 | 1.148 ± 0.4138 |
| Colonic Transit at 24 Hours, Day 2 | 1.965 ± 1.2964 | 3.792 ± 1.1441 | 3.468 ± 1.3252 | 2.978 ± 1.1382 |
| Colonic Transit at 48 Hours, Day 2 | 3.323 ± 1.2948 | 4.406 ± 1.1169 | 4.550 ± 0.9004 | 3.792 ± 1.0382 |
Colonic filling was estimated as percentage of the radio-labelled meal that reached the colon at Hour 6.
| percentage of radio-labelled food | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Colonic Filling at Hour 6 | 31.3 ± 25.38 | 55.6 ± 31.31 | 86.4 ± 19.76 | 75.3 ± 31.70 |
T1/2 of ascending colon emptying was estimated by analysis of proportionate emptying over time of counts from the colon. Scintigraphy assessments were used to evaluate the emptying of solids or liquids from ascending colon following a radio-labelled meal.
| hours | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Half-emptying Time (T1/2) of Ascending Colon | 19.1 (2.6 to 36.0) | 5.4 (1.9 to 28.8) | 6.3 (0.6 to 11.0) | 7.4 (0.9 to 13.6) |
| h*ng/mL | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|
| Day 1 | 8.99 ± 2.110 | 25.79 ± 8.340 | 83.75 ± 25.453 |
| Day 2 | 12.16 ± 3.033 | 33.94 ± 9.249 | 109.86 ± 31.009 |
| Day 3 | 15.72 ± 3.387 | 39.34 ± 12.699 | 125.88 ± 34.586 |
| ng/mL | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|
| Day 1 | 1.637 ± 0.3918 | 5.346 ± 1.5797 | 16.029 ± 2.9239 |
| Day 2 | 1.687 ± 0.4227 | 5.821 ± 1.9447 | 15.517 ± 3.7070 |
| Day 3 | 1.705 ± 0.3297 | 5.056 ± 1.5430 | 17.700 ± 7.1544 |
| ng/mL | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|
| Day 2 | 0.1969 ± 0.05406 | 0.4364 ± 0.20371 | 1.6817 ± 0.47072 |
| Day 3 | 0.2854 ± 0.10319 | 0.6392 ± 0.26371 | 2.2620 ± 0.40493 |
Collected over From first dose up to 30 days post last dose (Up to 46 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| TAK-954 0.1 mg | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| TAK-954 0.3 mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| TAK-954 1 mg | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Event | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| Pancreatic enzymes increasedInvestigations | 0/10 | 0/10 | 0/9 | 1/7 |
| Event | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/10 | 4/10 | 2/9 | 4/7 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 2/10 | 1/9 | 4/7 |
| HeadacheNervous system disorders | 0/10 | 1/10 | 3/9 | 1/7 |
| Abdominal painGastrointestinal disorders | 0/10 | 3/10 | 0/9 | 2/7 |
| Abdominal distensionGastrointestinal disorders | 2/10 | 0/10 | 1/9 | 2/7 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/10 | 0/10 | 0/9 | 2/7 |
| DehydrationMetabolism and nutrition disorders | 0/10 | 0/10 | 0/9 | 2/7 |
| DizzinessNervous system disorders | 0/10 | 0/10 | 1/9 | 2/7 |
| Viral infectionInfections and infestations | 0/10 | 2/10 | 0/9 | 0/7 |
| LeukocytosisBlood and lymphatic system disorders | 0/10 | 0/10 | 0/9 | 1/7 |
Safety analysis set included all subjects who receive at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Mean | 46.2 ± 15.67 | 46.8 ± 12.45 | 42.3 ± 11.82 | 40.3 ± 8.75 | 44.3 ± 12.45 |
| Sex: Female, Male(Participants) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Female | 8 | 10 | 7 | 5 | 30 |
| Male | 2 | 0 | 2 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 9 | 9 | 7 | 34 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| White | 10 | 10 | 9 | 7 | 36 |
| Disease History(Participants) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Idiopathic Gastroparesis | 7 | 7 | 3 | 5 | 22 |
| Diabetic Gastroparesis | 3 | 3 | 6 | 2 | 14 |
| Weight(kg) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Mean | 68.3 ± 15.05 | 73.4 ± 14.57 | 76.5 ± 17.97 | 62.5 ± 9.22 | 70.6 ± 15.07 |
| Height(cm) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Mean | 166.2 ± 9.37 | 160.7 ± 7.27 | 165.7 ± 5.92 | 166.3 ± 7.57 | 164.6 ± 7.74 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | TAK-954 0.1 mg | TAK-954 0.3 mg | TAK-954 1 mg | Total |
|---|---|---|---|---|---|
| Mean | 24.8 ± 4.88 | 28.4 ± 5.50 | 27.7 ± 5.44 | 22.6 ± 3.15 | 26.1 ± 5.24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2018 to primary completion in Jun 2019, 17 months.
Results were first posted in Jul 2020, 1 year 1 month after primary completion.
Of 20 phase 2 interventional studies under Gastroparesis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Td-8954